Research programme: human cytomegalovirus inhibitors - GPC Biotech/4SC
Alternative Names: HCMV kinase inhibitors - GPC Biotech/4SCLatest Information Update: 23 Jan 2007
Price :
$50 *
At a glance
- Originator 4SC; GPC Biotech AG
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 26 Apr 2006 No development reported - Preclinical for Cytomegalovirus infections treatment in Germany (unspecified route)
- 02 Mar 2005 Axxima Pharmaceuticals has been acquired and merged into GPC Biotech AG
- 03 Sep 2002 Preclinical trials in Cytomegalovirus infections in Germany (unspecified route)